Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

RBC maintains Outperform rating on Alnylam ahead of trial results

Published Feb 12, 2024 07:25AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
ALNY
+0.18%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

On Monday, RBC Capital Markets reiterated its Outperform rating on shares of Alnylam Pharmaceuticals, with a price target of $235.00. The firm's positive stance is based on an extensive review of clinical data related to treatments for patients with transthyretin-mediated cardiomyopathy (TTR-CM), a condition that Alnylam's therapies aim to address.

The analyst highlighted that while there is a lack of randomized data beyond the first 18-24 months in a trial that spans over 30 months, the strong cardiac benefit observed in the APOLLO-B trial supports confidence in a favorable outcome for the primary endpoint in the upcoming HELIOS-B study. This optimism is further bolstered by the pre-specified cardiac subgroup of the APOLLO trial and evidence suggesting that hard endpoints can be achieved despite advancements in medical management.

The potential for Alnylam's drug to demonstrate a clear advantage when used alongside tafamidis, another medication for TTR-CM, is still being determined. However, the analyst leans toward a positive outcome, noting that survival curves for silencers—like Alnylam's product—tend to diverge earlier than those for stabilizers and show a numerically lower mortality rate at 18-24 months. The different mechanisms of action between silencers and stabilizers are expected to have additive or synergistic effects.

RBC Capital also summarized feedback from the last 10 key opinion leader (KOL) calls, revealing a sentiment that skews heavily bullish, with 8 out of 10 expressing positive outlooks. Following a recent pullback in Alnylam's stock price, the firm sees an 18% risk-adjusted upside, which has been calculated by considering four different potential outcomes for the upcoming trial data.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

RBC maintains Outperform rating on Alnylam ahead of trial results
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email